高リン血症治療薬の世界市場

高リン血症治療薬の世界市場は2030年までに56億米ドルに達する見込み

2023年に40億米ドルと推定される高リン血症治療薬の世界市場は、2023年から2030年にかけてCAGR 5.0%で成長し、2030年には56億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるセベラマーは、CAGR 4.3%を記録し、分析期間終了時には22億米ドルに達すると予測されます。カルシウムベースのリン酸結合剤セグメントの成長率は、分析期間中CAGR 5.7%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR 8.1％で成長予測

米国の高リン血症治療薬市場は2023年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 8.1%で推移し、2030年には市場規模が12億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.0％と5.2％と予測されています。欧州では、ドイツがCAGR 3.0%で成長すると予測されています。

主要動向と促進要因

高リン血症は、血液中のリン酸濃度が異常に高いことを特徴とし、一般に慢性腎臓病（CKD）患者や透析患者に発症します。高リン酸血症は心血管疾患や骨障害などの重篤な症状を引き起こす可能性があるため、リン酸値の管理は極めて重要です。主な治療法としては、リン酸結合剤（消化管内でリン酸塩と結合して吸収を防ぐ薬）を使用します。結合剤には、炭酸カルシウムや酢酸カルシウムなどのカルシウム系化合物と、セベラマーや炭酸ランタンなどの非カルシウム系薬剤があり、高カルシウム血症を引き起こすリスクが低いため、これらの薬剤が好まれます。結合剤の選択は、患者の全身状態、リン酸値、既存の治療レジメンによって異なることが多いです。

リン酸塩結合剤に加えて、食事管理もリン値をコントロールする上で不可欠な要素です。しかし、進行したCKD患者や透析患者において安全なリン濃度を維持するためには食事療法だけでは限界があるため、より効果的で利便性の高い治療法の選択肢が絶えず求められています。最近の進歩は、新しい製剤や既存のリン酸塩結合剤の組み合わせに焦点が当てられており、患者の服薬アドヒアランスを改善し、副作用を最小限に抑えています。また、リン酸代謝のホルモン制御を標的とする薬剤の開発への関心も高まっており、食事性リン酸塩との結合にとどまらない新たな作用機序が期待されています。

高リン血症治療薬市場の成長は、糖尿病や高血圧の罹患率の上昇もあり、世界的に慢性腎臓病の有病率が増加していることなど、いくつかの要因によって牽引されています。透析治療の進歩によりCKD患者の寿命が延びていることも、リン酸値の長期管理を必要とする患者数の増加に寄与しています。さらに、より効果的な新しいリン酸塩結合剤の開発や、高リン血症に伴う合併症に対する意識の高まりも、これらの薬剤に対する需要を刺激しています。市場の拡大は、治療へのアクセスを改善するヘルスケア政策や、慢性疾患を抱える患者のQOL向上への関心の高まりも後押ししています。

調査対象企業の例（注目の51社）

• Akebia Therapeutics, Inc.
• Alebund Pharmaceuticals
• Ardelyx, Inc
• Chugai Pharmaceutical Co., Ltd.
• CSL Limited
• Dr. Paul Lohmann GmbH & Co. KGaA
• Fresenius Medical Care North America
• Kabir Lifesciences
• Kissei Pharmaceutical Co., Ltd
• Kyowa Kirin Co., Ltd.
• Macsen Laboratories
• Sanofi S.A.
• Taisho Pharmaceutical Holdings Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Torii Pharmaceutical Co., Ltd.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Hyperphosphatemia Drugs Market to Reach US$5.6 Billion by 2030

The global market for Hyperphosphatemia Drugs estimated at US$4.0 Billion in the year 2023, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Sevelamer, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Calcium-based Phosphate Binders segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 8.1% CAGR

The Hyperphosphatemia Drugs market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Key Trends and Drivers

Hyperphosphatemia, characterized by abnormally high phosphate levels in the blood, typically occurs in patients with chronic kidney disease (CKD) or those on dialysis. Managing phosphate levels is crucial as hyperphosphatemia can lead to serious conditions like cardiovascular disease and bone disorders. The primary treatment involves the use of phosphate binders—drugs that bind phosphate in the digestive tract to prevent its absorption. These binders include calcium-based compounds, such as calcium carbonate and calcium acetate, and non-calcium-based agents like sevelamer and lanthanum carbonate, which are preferred due to their lower risk of causing hypercalcemia. The choice of binder often depends on the patient's overall health, phosphate levels, and existing treatment regimen.

In addition to phosphate binders, dietary management is an integral part of controlling phosphorus levels. However, with the limitations of diet alone to maintain safe phosphorus levels in advanced CKD or dialysis patients, there is a continuous demand for more effective and convenient therapeutic options. Recent advances focus on new formulations and combinations of existing phosphate binders, improving patient adherence and minimizing side effects. There is also growing interest in developing drugs that target the hormonal regulation of phosphate metabolism, offering potential new mechanisms of action beyond binding dietary phosphate.

The growth in the hyperphosphatemia drugs market is driven by several factors, including the increasing prevalence of chronic kidney disease globally, due in part to rising rates of diabetes and hypertension. Advances in dialysis treatment increasing the longevity of CKD patients also contribute to a growing patient population requiring long-term management of phosphate levels. Furthermore, the development of new and more effective phosphate binders and the increasing awareness of the complications associated with hyperphosphatemia stimulate demand for these drugs. Market expansion is also supported by healthcare policies improving access to treatment and the growing focus on enhancing the quality of life for patients with chronic conditions.

Select Competitors (Total 51 Featured) -

• Akebia Therapeutics, Inc.
• Alebund Pharmaceuticals
• Ardelyx, Inc
• Chugai Pharmaceutical Co., Ltd.
• CSL Limited
• Dr. Paul Lohmann GmbH & Co. KGaA
• Fresenius Medical Care North America
• Kabir Lifesciences
• Kissei Pharmaceutical Co., Ltd
• Kyowa Kirin Co., Ltd.
• Macsen Laboratories
• Sanofi S.A.
• Taisho Pharmaceutical Holdings Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Torii Pharmaceutical Co., Ltd.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Hyperphosphatemia Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Kidney Disease and Its Impact on Market Growth
  • Innovations in Drug Formulations for Enhanced Phosphate Binding
  • Shift Towards Non-Calcium-Based Phosphate Binders
  • Impact of Aging Populations on Hyperphosphatemia Prevalence
  • Regulatory Changes and Their Impact on Drug Approvals
  • Advances in Personalized Medicine for Phosphate Management
  • Global Health Initiatives to Improve Renal Care
  • Patent Expiries and the Rise of Generic and Biosimilar Drugs
  • Technological Advancements in Drug Delivery Systems
  • Clinical Trials: Innovations and Challenges in Drug Development
  • Competitive Landscape and Strategic Alliances
  • Economic Factors Influencing Drug Affordability and Access
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Hyperphosphatemia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Hyperphosphatemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Hyperphosphatemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Sevelamer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Sevelamer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Sevelamer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Calcium-based Phosphate Binders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Calcium-based Phosphate Binders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Calcium-based Phosphate Binders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Iron-based Phosphate Binders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Iron-based Phosphate Binders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Iron-based Phosphate Binders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Lanthanum Carbonate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Lanthanum Carbonate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Lanthanum Carbonate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Tablets Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Tablets Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Tablets Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Syrups Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Syrups Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Syrups Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Capsules Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• JAPAN
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• CHINA
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: China 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• EUROPE
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Hyperphosphatemia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Hyperphosphatemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• FRANCE
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: France 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: France 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• GERMANY
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Hyperphosphatemia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Hyperphosphatemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• INDIA
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: India 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: India 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: India 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Hyperphosphatemia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Hyperphosphatemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Hyperphosphatemia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Hyperphosphatemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030
• AFRICA
  • Hyperphosphatemia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Hyperphosphatemia Drugs by Product - Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Hyperphosphatemia Drugs by Product - Percentage Breakdown of Value Sales for Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate and Other Products for the Years 2014, 2024 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Hyperphosphatemia Drugs by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Hyperphosphatemia Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2014, 2024 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Hyperphosphatemia Drugs by Dosage Form - Tablets Form, Syrups Form and Capsules Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Hyperphosphatemia Drugs by Dosage Form - Percentage Breakdown of Value Sales for Tablets Form, Syrups Form and Capsules Form for the Years 2014, 2024 & 2030

IV. COMPETITION